Shares of BioNTech SE BNTX, +0.65% gained 0.9% in premarket trading on Monday after the company told investors that it nearly doubled its estimate for the amount of coronavirus vaccine it plans to produce in 2021. BioNTech said in a regulatory filing that it now expects to manufacture 2 billion doses of its COVID-19 vaccine this year, up from previous estimates of 1.3 billion. BioNTech partnered with Pfizer Inc. PFE, -0.12% on its vaccine, which has received emergency authorization in the U.S. as well as in several other nations. Their vaccine requires two doses so the new estimates means they may be able to vaccinate 1 billion people in 2021. BioNTech’s stock is up 303.3% over the past year, while the S&P 500 SPX, +0.68% has gained 13.4%.
View Article Origin Here
